Phase II study of vemurafenib followed by ipilimumab in patients with previously untreated BRAF-mutated metastatic melanoma

BACKGROUND: Ipilimumab (IPI), an anti-CTLA-4 antibody, and vemurafenib (VEM), a BRAF inhibitor, have distinct mechanisms of action and shared toxicities (e.g., skin, gastrointestinal [GI] and hepatobiliary disorders) that may preclude concomitant administration. Concurrent administration of IPI and...

Descripción completa

Detalles Bibliográficos
Autores principales: Amin, Asim, Lawson, David H., Salama, April K.S., Koon, Henry B., Guthrie, Troy, Thomas, Sajeve S., O’Day, Steven J., Shaheen, Montaser F., Zhang, Bin, Francis, Stephen, Hodi, F. Stephen
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BioMed Central 2016
Materias:
Research Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4986368/
https://www.ncbi.nlm.nih.gov/pubmed/27532019
http://dx.doi.org/10.1186/s40425-016-0148-7

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4986368/
https://www.ncbi.nlm.nih.gov/pubmed/27532019
http://dx.doi.org/10.1186/s40425-016-0148-7

Ejemplares similares